Pipeline › petrelintide
petrelintide
Not FDA-approved, and in phase 2 development, not authorised in the European Union. 4 active trials, the next due to complete 2027-11-12.
amylin agonist, SC, from Zealand Pharma. Every figure below is taken directly from ClinicalTrials.gov, Drugs@FDA, the FDA Drug Shortage Database, the EMA register or Europe PMC, and re-checked every four hours.
- Status
- phase2
- Target
- amylin
- Route
- SC
- Sponsor
- Zealand Pharma
- First FDA approval
- Not approved
- EU authorisation
- Not authorised
- Active trials
- 4 (3 in phase 3)
- Participants enrolled
- 7,486
- Trials with a reporting date
- 3
- Approved FDA submissions
- 0
Recent changes
When these trials report
Next 3 of 3 active trials by estimated primary completion.
| Est. completion | Trial | Sponsor | Phase | Participants |
|---|---|---|---|---|
| 2027-11-12 | A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight NCT07589686 · Percentage Change in Body Weight between Arms 1 and 6 | Hoffmann-La Roche | P2 | 486 |
| 2028-10-20 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes NCT07843485 · Percentage Change in Body Weight from Baseline | Hoffmann-La Roche | P3 | 600 |
| 2028-12-21 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity NCT07843498 · Percentage Change in Body Weight from Baseline | Hoffmann-La Roche | P3 | 3,900 |
Indications under study
Cardiovascular Disease; Obesity or Overweight; Type 2 Diabetes.
Recent papers
| Published | Title | Journal |
|---|---|---|
| 2026-09-29 | Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial Garvey WT, Ard J, Connery L, Frias JP, le Roux CW, Pietiläinen KH, Dinesen M, Hagen BF, Larsen L, Hesse D, Kendall DM. | Lancet Diabetes Endocrinol |
| 2026-09-29 | Petrelintide and the evolving role of amylin agonism in obesity Madsbad S, Holst JJ. | Lancet Diabetes Endocrinol |
| 2026-04-22 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials Brændholt Olsen M, Griffin J, Hövelmann U, Macura S, Fredsted Hagen B, Hesse D, Heise T. | Diabetes Obes Metab |
| 2025-11-11 | Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue Fischer Munch H, Just R, Mosolff Mathiesen J, Eriksson PO, Skodborg Villadsen J, Vestergaard B, Deryabina M, Demmer O, Skarbaliene J, Hamprecht DW, Rist W, Baader-Pagler T, Grube A, Heim-Riether A, Giehm L. | J Med Chem |
Every petrelintide trial on file
All 6 registered trials of petrelintide, largest first. Each links to its own page and to the registry record.